Business
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss, to be presented in an oral sessionSHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage por
About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A
[{"type":"image","alt":"Kailera Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kailera Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/e0d3565801d0638c4e04d01b2e1d4aa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0Jn2mPB37gXI37kJYUq7wQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e0d3565801d0638c4e04d01b2e1d4aa0","width":300,"height":169}},"lazy":false},{"type":"text","content":"Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss, to be presented in an oral session","length":189,"tagName":"p"},{"type":"text","content":"SHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced an oral presentation at ObesityWeek® 2025, the annual meeting of the Obesity Society, taking place November 4-7, 2025, in Atlanta, GA.","length":527,"tagName":"p"},{"type":"text","content":"The presentation will detail results from Hengrui’s Phase 3 clinical trial (GEMINI-1) conducted in China of once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in individuals living with obesity or overweight. Topline results from the trial were previously reported indicating the potential for category-leading weight loss","length":359,"tagName":"p"},{"type":"text","content":"The following abstract was submitted by Hengrui and accepted for presentation:","length":78,"tagName":"p"},{"type":"text","content":"Oral presentation: Friday, November 7, 8:30 a.m. ETAbstract Oral-103: Phase 3 Trial of HRS9531, a GLP-1/GIP Receptor Agonist, in Chinese Adults with Overweight or Obesity","length":171,"tagName":"p"},{"type":"text","content":"All abstracts will be published online in the journal Obesity and the presentation will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found ...
More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A